Merck ups 見通し, turns 利益（をあげる） during 全世界の ワクチン 追跡（する）
FAIRLESS HILLS, PA (AP) - 殺到するing sales of 癌 薬／医学s and 減ずるd spending across the board helped Merck 打ち勝つ a big 攻撃する，衝突する from the coronavirus pandemic and 押し進めるd second ４半期/4分の1 利益（をあげる）s up by 12%.
The drugmaker blew past 塀で囲む Street 発射／推定s and 上げるd its 財政上の 予測（する） for the year Friday even as it spends ひどく on the 開発 of two 実験の ワクチンs and a possible 治療 for COVID-19.
"顧客 接近 to care is 改善するing," said CEO Kenneth Frazier, 追加するing that he is 楽観的な about ワクチンs and a 治療 for COVID-19.
Unlike many 競争相手s developing ワクチンs that will 要求する two doses, Merck is 目的（とする）ing for one-dose ワクチンs.
The company bought Austrian ワクチン 製造者 Themis Biosciences this year to 伸び（る） 権利s to its 実験の COVID-19 ワクチン. Human 実験（する）s should begin this ４半期/4分の1. Human 実験（する）ing on a second type of ワクチン, 存在 developed with an international nonprofit ワクチン 国際借款団／連合, is 推定する／予想するd to begin this year. The latter uses the 科学（工学）技術 that´s the basis for Merck´s 認可するd ワクチン against the Ebola ウイルス, which could 改善する chances for success against COVID-19.
Merck ーするつもりであるs to try to get both 認可するd, rather than 選ぶing the best one, because it 推定する／予想するs 多重の ワクチンs will be needed to 保護する different 患者 groups, 研究 長，率いる Roger Perlmutter said Friday.
FILE- This May 1, 2018, とじ込み／提出する photo shows Merck 法人組織の／企業の （警察，軍隊などの）本部 in Kenilworth, N.J. The pandemic 増加するd sales of Merck 薬／医学s during the first ４半期/4分の1 of 2020, as 世帯s around the world 在庫／株d up, but the drugmaker 推定する／予想するs a 重要な 攻撃する，衝突する this ４半期/4分の1 as the 十分な 軍隊 of the 突発／発生 lands. (AP Photo/Seth Wenig, とじ込み／提出する)
The company already has 安全な・保証するd capacity to 製造（する） many millions of doses of the ワクチン before the end of 2020, Frazier said. He said Merck is committed to "affordable and equitable 接近" to its 治療s and ワクチンs.
In 新規加入, Merck and partner Ridgeback Bio are developing a coronavirus 治療 that was 井戸／弁護士席 許容するd by 患者s in 早期に 熟考する／考慮するs. In September, they 計画（する） to start two large 裁判，公判s that could lead to 是認, with one for 患者s 入院させるd with the ウイルス and another for those 存在 扱う／治療するd as outpatients.
"I am 楽観的な that we will be able to 減ずる the 衝撃 of this 破滅的な pandemic," Perlmutter said.
While it 追求するs 治療s, COVID-19 is 傷つけるing Merck. The company said Friday that people are 延期するing visits to both doctors and veterinarians. Merck makes 麻薬s for both people and animals.
歳入 fell 8%, to $10.87 billion, from $11.76 billion.
However, sales of immuno-oncology blockbuster Keytruda and other 癌 麻薬s rose, partly 予定 to 是認s for new uses or 患者 groups.
逮捕する income reached $3.0 billion, or $1.18 per 株, up from $2.67 million, or $1.03 per 株, a year earlier.
Adjusted for one-time items, income was $3.48 billion, or $1.37 per 株.
分析家s 調査するd by FactSet were 推定する／予想するing adjusted 収入s of $1.06 per 株 and sales of $10.4 billion.
The Kenilworth, New Jersey, company said it now 推定する／予想するs 年次の 歳入 of between $47.2 billion and $48.7 billion, and adjusted per-株 収入s between $5.63 and $5.78. That´s up from its April 予測（する） of between $46.1 billion and $48.1 billion in 歳入 and 収入s per 株 of $5.17 to $5.37.
Sales of prescription 薬／医学s dropped 7%, to $9.68 billion. Nearly all of Merck's 重要な 麻薬s 苦しむd sales 拒絶する／低下するs, 特に those 治めるd in hospitals and pediatric ワクチンs 治めるd in doctors' offices. Sales of 薬／医学s for pets and livestock dipped 2%, to $1.1 billion, partly 予定 to restaurant 終結s cutting 需要・要求する for protein.
Keytruda continued its impressive growth toward 潜在的に becoming the world´s 最高の，を越す-selling 薬／医学, with 歳入 急に上がるing 29% in the ４半期/4分の1, to $3.39 billion. 歳入 also jumped for Lynparza and Lenvima, two 癌 麻薬s it sells with partner AstraZeneca.
"にもかかわらず the challenges, Merck is 遂行する／発効させるing 井戸／弁護士席," with its new 指導／手引 now わずかに above its 2020 財政上の 予測（する） 問題／発行するd before the pandemic, Edward Jones 分析家 Ashtyn Evans wrote. She 公式文書，認めるd that sales were 減ずるd by $1.6 billion, "as 需要・要求する for doctor-治めるd 麻薬s and ワクチンs 拒絶する／低下するd and there were より小数の new 診断するs."
Merck & Co. 株 rose 1% to $79.80 in midday 貿易（する）ing Friday.
